Bone Cancer: Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Primary bone cancer encompasses malignancies arising directly from bone cells and their precursors — distinct from the far more common secondary bone metastases originating from carcinomas of other organs. Approximately 3,900 new primary bone cancer cases occur annually in the United States, and primary bone malignancies represent fewer than 0.2% of all new cancer diagnoses. The three principal subtypes are osteosarcoma (bone-forming tumor — the most common primary bone malignancy, approximately 35% of cases, predominantly affecting adolescents and young adults), Ewing sarcoma (a small round-cell tumor of neuroectodermal origin, approximately 16% of primary bone cancers, predominantly children and young adults — the second most common primary bone malignancy under age 20), and chondrosarcoma (cartilage-forming tumor, approximately 30% of primary bone cancers, predominantly affecting adults over 40 — the most common primary bone malignancy in adults). Giant cell tumor of bone (GCTB), chordoma, fibrosarcoma, and undifferentiated pleomorphic sarcoma (UPS) account for additional cases. Secondary bone metastases from breast, prostate, lung, kidney, and thyroid cancers are approximately 25-fold more frequent than primary bone cancers and should be the primary diagnostic consideration in adults with bone lesions. The distinction is clinically critical — osteosarcoma and Ewing sarcoma are highly chemotherapy-sensitive (integrated chemotherapy plus surgery achieves 5-year OS of 65-75% for localized disease), while chondrosarcoma is largely chemoresistant (surgery alone is the treatment). Multimodal management at specialized orthopedic oncology centers is essential; limb-salvage surgery has replaced amputation as the standard approach in approximately 90% of osteosarcoma patients.

Each primary bone cancer subtype has distinct oncogenic mechanisms and predisposing factors. Osteosarcoma: arises from committed osteoblast precursors undergoing malignant transformation; the adolescent peak reflects the mitotic activity of bone-forming cells during pubertal growth spurts — particularly at the metaphyses of the most rapidly growing long bones (distal femur, proximal tibia, proximal humerus). Hereditary predisposition: germline RB1 mutations (retinoblastoma survivors — RB1 on chromosome 13q14 encodes the retinoblastoma tumor suppressor protein; retinoblastoma survivors have a 500-fold elevated osteosarcoma risk due to RB1 loss in osteoblasts); Li-Fraumeni syndrome (germline TP53 mutation) substantially increases osteosarcoma risk — TP53 somatic mutations are present in approximately 20-30% of sporadic osteosarcoma. Prior ionizing radiation: therapeutic radiation to bone (for any cancer) is a recognized cause of secondary osteosarcoma, developing 5-20 years after exposure. Paget disease of bone: pre-malignant condition of disordered osteoclastic and osteoblastic activity — secondary osteosarcoma complicates approximately 1% of Paget disease cases. Somatic molecular alterations in osteosarcoma: complex genomic instability with multiple chromosomal copy number variations, TP53 and RB1 somatic mutations, CDK4/MDM2 amplification in low-grade central osteosarcoma, and DLG2 mutations. Ewing sarcoma: driven by balanced chromosomal translocations creating oncogenic fusion proteins — most commonly t(11;22)(q24;q12) producing EWSR1-FLI1 fusion transcript in approximately 85% of cases; EWSR1-ERG fusion t(21;22) in approximately 10%; all EWSR1 rearrangements produce aberrant transcription factor activity driving small round-cell sarcomagenesis; no hereditary predisposition identified; no established environmental risk factors. Chondrosarcoma: conventional chondrosarcoma arises sporadically in middle-aged adults; Ollier disease (enchondromatosis — multiple intraosseous enchondromas, IDH1/IDH2 mutations) confers substantially elevated chondrosarcoma risk (25-30% lifetime); Maffucci syndrome (enchondromatosis plus soft tissue hemangiomas, IDH mutations) carries the highest risk (~50% risk); prior radiotherapy is a recognized cause of secondary chondrosarcoma; the IDH1 R132C mutation is the most common somatic mutation in low-grade chondrosarcoma, enabling IDH inhibitor targeting in IDH-mutated disease.

The clinical presentation of primary bone cancer shares common features but also has subtype-specific characteristics that may aid differentiation from benign bone pathology and secondary bone metastases. Persistent, progressive bone pain is the hallmark symptom across all primary bone cancer types — it is characteristically dull and aching at rest, worsening with activity and often most pronounced at night when the patient is recumbent (nocturnal pain), and is not relieved by standard analgesics or NSAIDS; it tends to worsen progressively over weeks to months rather than fluctuating. Palpable soft tissue mass or swelling around the affected bone: a visible or palpable swelling — often warm, tender, and firm — directly overlying the tumor in a long bone metaphysis; rapid growth of a bone swelling is a red-flag feature requiring urgent investigation. Pathological fracture: fracture through weakened, tumor-infiltrated bone occurring with minimal or no trauma — may be the presenting event in up to 15-20% of osteosarcomas and higher rates in metastatic deposits; typically through the weakened cortex at the tumor site. Limited range of motion: stiffness and restricted movement of the adjacent joint — from periarticular inflammation, effusion, or direct joint involvement by tumor growing across the physis. Osteosarcoma-specific features: typically metaphyseal location (distal femur 45%, proximal tibia 20%, proximal humerus 15%); tumor crossing the growth plate into the epiphysis in adolescents; elevated serum alkaline phosphatase (reflecting disordered osteoblastic activity — approximately 50-60% of osteosarcoma patients) and elevated serum LDH (prognostically adverse). Ewing sarcoma-specific features: systemic inflammatory features mimicking osteomyelitis — low-grade fever (37.5-38.5°C), malaise, weight loss, elevated ESR, and elevated CRP — reflecting tumor-related inflammatory cytokine secretion; these features frequently lead to initial incorrect antibiotic treatment; Ewing sarcoma may affect mid-diaphysis of long bones (in contrast to osteosarcoma's metaphyseal predilection) and flat bones (pelvis, scapula, ribs) in approximately 50%. Chondrosarcoma-specific features: typically deep-seated, poorly localized pain in the pelvis, ribs, or proximal limb bones; may grow insidiously for months to years before diagnosis; chondrosarcoma is the most common primary malignancy of the pelvis and axial skeleton in adults.

Biopsy is the definitive diagnostic procedure but must never be performed before appropriate imaging, as biopsy track contamination can compromise limb-salvage surgery planning. Plain radiography is the mandatory first investigation for any suspected bone tumor: osteosarcoma — mixed sclerotic and lytic destructive metaphyseal lesion with aggressive periosteal reaction (sunburst pattern from radially expanding osteoid; Codman triangle — elevation of periosteum at tumor margin lifting a corner of periosteum); Ewing sarcoma — permeative destructive diaphyseal lesion with multi-laminated periosteal reaction (onion-skin layering) and associated soft tissue mass; chondrosarcoma — lobulated lytic lesion with endosteal scalloping, popcorn or ring-and-arc chondroid calcifications, and cortical thickening. MRI of the primary tumor (with gadolinium): the gold standard for characterizing local tumor extent, intramedullary marrow infiltration, cortical breakthrough, soft tissue component, neurovascular involvement, and skip lesions (discontinuous satellite foci in the same bone compartment — present in approximately 10% of osteosarcoma); critical for surgical planning and determining the level of bone resection needed to achieve clear margins. CT chest: mandatory staging for pulmonary metastases — the most common distant site (85% of metastatic osteosarcoma and Ewing sarcoma have pulmonary involvement); thin-slice CT identifies subcentimeter nodules. PET-CT (18F-FDG) or technetium-99m bone scan: whole-body skeletal staging for polyostotic involvement and distant bone metastases. Core needle biopsy (14G or 16G core needles, CT-guided or fluoroscopy-guided) placed along the planned surgical approach — provides histological diagnosis with adequate tissue for IHC, FISH for EWSR1 rearrangement, and molecular studies. Open incisional biopsy: reserved for cases where core needle biopsy is non-diagnostic; must be performed along the planned definitive resection incision at an experienced orthopedic oncology center. Bone marrow aspirate/biopsy: bilateral iliac crest sampling for Ewing sarcoma staging (bone marrow metastasis in approximately 10%). AJCC 8th edition TNM staging for bone sarcoma: T1 (below 8 cm), T2 (above 8 cm), T3 (discontinuous skip lesions); Enneking surgical staging (IA, IB, IIA, IIB, III, IVA, IVB) guides surgical approach and extent of resection. Serum alkaline phosphatase and LDH are prognostic markers in osteosarcoma — elevation correlates with higher metastatic risk and worse outcomes.

Osteosarcoma — standard multimodal treatment: neoadjuvant chemotherapy (MAP regimen: high-dose methotrexate 12 g/m2 IV with leucovorin rescue days 1 and 8; doxorubicin 75 mg/m2 continuous infusion days 1-3; cisplatin 120 mg/m2 day 1; cycle length 35 days for 3 pre-operative cycles) → limb-salvage surgery (or amputation when anatomically unavoidable) → adjuvant MAP chemotherapy (3 additional cycles); the histological tumor necrosis rate in the resected specimen after neoadjuvant therapy is the most powerful prognostic factor — good response (above 90% necrosis) predicts 5-year OS of approximately 80-85% vs 50-60% for poor responders; limb-salvage surgery achieves negative margins in approximately 90% of patients, using modular endoprosthetic reconstruction (segmental replacement prostheses), allograft reconstruction, or autograft (fibular free flap for small bones). Pulmonary metastasectomy for limited lung metastases is performed at surgery and may achieve cure in a minority of patients. Gemcitabine plus docetaxel, sorafenib (SUCCEED trial: PFS 4 vs 1.4 months), regorafenib, and cabozantinib are used in relapsed/refractory settings. Ewing sarcoma — standard multimodal treatment: VIDE induction chemotherapy (vincristine 1.5 mg/m2, ifosfamide 9 g/m2, doxorubicin 20 mg/m2 days 1-3, etoposide 150 mg/m2 days 1-3; 6 cycles every 3 weeks) → local control (surgery and/or EBRT) → consolidation chemotherapy (VAI: vincristine, dactinomycin, ifosfamide; or VAC: vincristine, dactinomycin, cyclophosphamide); high-risk Ewing (metastatic, large tumors): busulfan-melphalan high-dose chemotherapy with autologous SCT (EURO-EWING 2012: superior outcomes vs carboplatin-etoposide-melphalan); definitive radiotherapy (54-60 Gy) when complete surgical resection requires unacceptable functional deficit (pelvis, spine); Ewing sarcoma is far more radiosensitive than osteosarcoma. Chondrosarcoma: wide surgical resection with clear margins is the only effective treatment for conventional grades I-III chondrosarcoma — chemotherapy (standard sarcoma regimens) and radiotherapy are largely ineffective; surgical approach ranges from extended curettage with local adjuvant (phenol, argon beam, liquid nitrogen cryosurgery) for low-grade (grade 1) chondrosarcoma to radical resection or hemipelvectomy for high-grade or pelvic chondrosarcoma; dedifferentiated chondrosarcoma: doxorubicin plus ifosfamide (standard sarcoma regimens, though response rates are lower than for other sarcomas); IDH-mutated chondrosarcoma: ivosidenib (IDH1-mutated) or enasidenib (IDH2-mutated) — preliminary data showing disease control. Immune checkpoint inhibitors: pembrolizumab modest activity in bone sarcomas generally (ORR approximately 5-10%).

Primary bone cancer prognosis varies significantly by histological type, stage, and response to treatment. Localized osteosarcoma treated with MAP chemotherapy (methotrexate, doxorubicin, cisplatin) plus limb-salvage surgery achieves 5-year overall survival of approximately 65-70%; metastatic osteosarcoma at presentation carries 5-year survival of approximately 20-30%. The histological tumor necrosis rate after neoadjuvant chemotherapy is the strongest independent prognostic factor — good responders with above 90% necrosis achieve 5-year survival of approximately 80-85% versus approximately 50-60% for poor responders. Localized Ewing sarcoma treated with VIDE chemotherapy plus surgery and/or radiotherapy achieves 5-year overall survival of approximately 60-70%; metastatic Ewing sarcoma (bone and/or lung metastases) carries 5-year survival of approximately 15-30%. Bone-only metastases in Ewing sarcoma carry worse prognosis than lung-only metastases. Conventional chondrosarcoma prognosis is heavily grade-dependent: Grade I carries 5-year survival exceeding 90% with adequate surgery; Grade II approximately 80%; Grade III approximately 50-65%. Dedifferentiated chondrosarcoma — even with multimodal therapy — carries 5-year survival of approximately 20-30%. Clear cell chondrosarcoma and mesenchymal chondrosarcoma have distinct prognoses. Across all bone cancers, achieving adequate surgical margins (wide or radical resection with R0 margins) is the single most important modifiable prognostic factor. Pulmonary metastasectomy for limited resectable lung metastases achieves cure in a small but meaningful minority of osteosarcoma patients. Late effects of treatment require lifelong surveillance — cardiac toxicity from anthracyclines (regular echocardiography), hearing loss from cisplatin (audiograms), limb prosthesis complications, infertility from alkylating agents, and secondary malignancies from chemotherapy and radiation.

Most primary bone cancers cannot be prevented, as they arise from sporadic genetic mutations without known modifiable environmental triggers. Individuals with hereditary predisposing syndromes — Li-Fraumeni syndrome (TP53 germline mutation), retinoblastoma survivors (RB1 mutation), Ollier disease (IDH1/2 mutations), and Maffucci syndrome — require regular skeletal surveillance and prompt evaluation of any new bone pain or swelling. Prior radiotherapy to bone — a known secondary osteosarcoma risk factor — should be reserved for situations where the benefit clearly outweighs risk. Pathological fractures from Paget disease of bone, which predisposes to secondary osteosarcoma in older adults, can be partially prevented by adequate bisphosphonate treatment of active Paget disease. Prompt evaluation of unexplained bone pain in children and adolescents reduces delay in diagnosis, which is a key determinant of metastatic spread at presentation.

Persistent bone or joint pain in a child or adolescent that is progressive, not clearly attributable to sports injury, worsens at night, or is associated with a palpable mass must be evaluated promptly — osteosarcoma and Ewing sarcoma are frequently misdiagnosed as growing pains or sports injuries. A new bone swelling or visible deformity at a bone, particularly in the long bones of the extremities, requires urgent imaging. Ewing sarcoma may present with fever, elevated inflammatory markers, and local warmth mimicking bone infection — biopsy is essential when osteomyelitis does not respond as expected to antibiotics. A pathological fracture — a fracture through abnormal bone with minimal or no trauma — requires urgent investigation for an underlying bone tumor or metastasis. Adults over 40 with unexplained bone pain and a prior history of radiation or enchondromatosis should be assessed for chondrosarcoma.